about
Tumor bed radiosurgery: an emerging treatment for brain metastases.Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.Distribution of Cervical Lymph Node Metastases From Squamous Cell Carcinoma of the Oropharynx in the Era of Risk Stratification Using Human Papillomavirus and Smoking Status.Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration.A Dose-Volume Response Model for Brain Metastases Treated With Frameless Single-Fraction Robotic Radiosurgery: Seeking to Better Predict Response to TreatmentIncreasing time to postoperative stereotactic radiation therapy for patients with resected brain metastases: investigating clinical outcomes and identifying predictors associated with time to initiation.Effect of time to simulation and treatment for patients with oropharyngeal cancer receiving definitive radiotherapy in the era of risk stratification using smoking and human papillomavirus status.Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.Neck dissection for unknown cancer of the head and neck in the era of chemoradiation.High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.Stereotactic Ablative Radiotherapy for a Lung Metastasis in a Child With Ewing's Sarcoma.Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes.Simultaneous integrated boost using stereotactic radiosurgery for resected brain metastases: rationale, dosimetric parameters, and preliminary clinical outcomesSuccessful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancerSpot scanning proton therapy for craniopharyngioma
P50
Q38441512-412D8655-A153-4036-9237-89A0406C46E4Q38815311-0758EA62-6AAB-4E0C-B013-F0CCC962578CQ39419259-99977CED-A9EB-4712-B6BE-ED419549A396Q41475918-AAEAADB7-0C0B-498F-B1C6-E3BA6E300305Q42282636-A1DF3B1A-3056-4D19-AC56-2AC832AB6502Q47967318-861E7B91-2019-4F3B-BCAB-40209F73BF65Q48197186-F9C91BA8-6C6E-43A2-9209-FED2DDAD70C9Q48317569-DC13B918-A9FB-4376-918B-004758A71EA3Q52765037-89672E66-94F1-4DD7-B97B-24BC594B4C33Q52779333-91BB4361-50FD-48C2-B301-8A5E2F9F0490Q52982360-D1224622-2BBF-4713-9AB5-767B216C86D9Q55457244-0EC21553-A1A6-4624-B524-FE4300363359Q55462339-10E28E42-6C49-4301-9878-AC89E55506BEQ85896410-EC80034F-AC69-4210-B781-1C6209A78605Q86076757-231BDA1B-7465-43CF-8FAE-5211C808E63BQ87534375-EEAF4846-0865-47E9-BB2A-12A3B7474644
P50
description
researcher ORCID ID = 0000-0003-1268-3569
@en
wetenschapper
@nl
name
Mark J Amsbaugh
@ast
Mark J Amsbaugh
@en
Mark J Amsbaugh
@es
Mark J Amsbaugh
@nl
type
label
Mark J Amsbaugh
@ast
Mark J Amsbaugh
@en
Mark J Amsbaugh
@es
Mark J Amsbaugh
@nl
prefLabel
Mark J Amsbaugh
@ast
Mark J Amsbaugh
@en
Mark J Amsbaugh
@es
Mark J Amsbaugh
@nl
P1153
54890725600
P31
P496
0000-0003-1268-3569